Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide: A population-based case-control study

Benjamin Daniels; Sallie Anne Pearson; Claire M. Vajdic; Anton Pottegård; Nicholas A. Buckley; Helga Zoega

doi:10.1111/bcpt.13463

Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide: A population-based case-control study

Benjamin Daniels^*, Sallie Anne Pearson, Claire M. Vajdic, Anton Pottegård, Nicholas A. Buckley, Helga Zoega

^*Corresponding author for this work

Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Recent European and US studies reported increased risks of skin cancers associated with hydrochlorothiazide (HCTZ) treatment. Our study aimed to determine the risk of lip cancer and malignant melanoma among Australians prescribed HCTZ. We conducted a case-control study nested within a population of veterans residing in New South Wales in 2004-2015, using Australian Department of Veterans’ Affairs data linked with cancer registrations, hospitalisation and prescription dispensings. Among DVA healthcare card holders 65 years and older, we identified incident cases of squamous cell carcinoma of the lip and of cutaneous melanoma, each matched with up to 20 controls through risk-set sampling. We estimated odds ratios (ORs) associating HCTZ use with each cancer using conditional logistic regression, adjusting for predefined confounders. For lip cancer (45 cases), ever-use of HCTZ yielded an OR of 2.6 (95% CI: 1.4-5.0) and high HCTZ use (≥25 000 mg) an OR of 4.7 (95% CI: 1.6-13.7). For cutaneous melanoma (659 cases), ever-use of HCTZ resulted in an OR of 1.2 (95% CI 1.0-1.5) and high HCTZ use in an OR of 1.2 (95% CI: 0.8-1.8). Our findings align with risk estimates from previous studies and provide further evidence that HCTZ’s photosensitising properties may promote carcinogenesis in sun-exposed tissues.

Original language	English
Pages (from-to)	320-328
Number of pages	9
Journal	Basic and Clinical Pharmacology and Toxicology
Volume	127
Issue number	4
DOIs	https://doi.org/10.1111/bcpt.13463
Publication status	Published - 1 Oct 2020

Bibliographical note

Funding information
This work was supported by the Australian Government Department of Health, the NHMRC Centre of Research Excellence in Medicines and Ageing (CREMA; ID: 1060407), and a Cooperative Research Centre Project (CRC-P) Grant from the Australian Government Department of Industry, Innovation and Science (ID: CRC-P-439). CMV and HZ are supported by UNSW Scientia Fellowships. The funders of the study had no role in the data analysis, interpretation or drafting of the final manuscript.

Publisher Copyright:
© 2020 Commonwealth of Australia. © 2020 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)

Other keywords

Australia
hydrochlorothiazide
lip cancer
malignant melanoma
skin cancer

Access to Document

10.1111/bcpt.13463

Cite this

@article{2552c0d8d1a34070b8e2b5cb5015102c,

title = "Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide: A population-based case-control study",

abstract = "Recent European and US studies reported increased risks of skin cancers associated with hydrochlorothiazide (HCTZ) treatment. Our study aimed to determine the risk of lip cancer and malignant melanoma among Australians prescribed HCTZ. We conducted a case-control study nested within a population of veterans residing in New South Wales in 2004-2015, using Australian Department of Veterans{\textquoteright} Affairs data linked with cancer registrations, hospitalisation and prescription dispensings. Among DVA healthcare card holders 65 years and older, we identified incident cases of squamous cell carcinoma of the lip and of cutaneous melanoma, each matched with up to 20 controls through risk-set sampling. We estimated odds ratios (ORs) associating HCTZ use with each cancer using conditional logistic regression, adjusting for predefined confounders. For lip cancer (45 cases), ever-use of HCTZ yielded an OR of 2.6 (95% CI: 1.4-5.0) and high HCTZ use (≥25 000 mg) an OR of 4.7 (95% CI: 1.6-13.7). For cutaneous melanoma (659 cases), ever-use of HCTZ resulted in an OR of 1.2 (95% CI 1.0-1.5) and high HCTZ use in an OR of 1.2 (95% CI: 0.8-1.8). Our findings align with risk estimates from previous studies and provide further evidence that HCTZ{\textquoteright}s photosensitising properties may promote carcinogenesis in sun-exposed tissues.",

keywords = "Australia, hydrochlorothiazide, lip cancer, malignant melanoma, skin cancer",

author = "Benjamin Daniels and Pearson, {Sallie Anne} and Vajdic, {Claire M.} and Anton Potteg{\aa}rd and Buckley, {Nicholas A.} and Helga Zoega",

note = "Funding information This work was supported by the Australian Government Department of Health, the NHMRC Centre of Research Excellence in Medicines and Ageing (CREMA; ID: 1060407), and a Cooperative Research Centre Project (CRC-P) Grant from the Australian Government Department of Industry, Innovation and Science (ID: CRC-P-439). CMV and HZ are supported by UNSW Scientia Fellowships. The funders of the study had no role in the data analysis, interpretation or drafting of the final manuscript. Publisher Copyright: {\textcopyright} 2020 Commonwealth of Australia. {\textcopyright} 2020 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)",

year = "2020",

month = oct,

day = "1",

doi = "10.1111/bcpt.13463",

language = "English",

volume = "127",

pages = "320--328",

journal = "Basic and Clinical Pharmacology and Toxicology",

issn = "1742-7835",

publisher = "Wiley-Blackwell",

number = "4",

}

Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide: A population-based case-control study. / Daniels, Benjamin; Pearson, Sallie Anne; Vajdic, Claire M. et al.
In: Basic and Clinical Pharmacology and Toxicology, Vol. 127, No. 4, 01.10.2020, p. 320-328.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide

T2 - A population-based case-control study

AU - Daniels, Benjamin

AU - Pearson, Sallie Anne

AU - Vajdic, Claire M.

AU - Pottegård, Anton

AU - Buckley, Nicholas A.

AU - Zoega, Helga

N1 - Funding information This work was supported by the Australian Government Department of Health, the NHMRC Centre of Research Excellence in Medicines and Ageing (CREMA; ID: 1060407), and a Cooperative Research Centre Project (CRC-P) Grant from the Australian Government Department of Industry, Innovation and Science (ID: CRC-P-439). CMV and HZ are supported by UNSW Scientia Fellowships. The funders of the study had no role in the data analysis, interpretation or drafting of the final manuscript. Publisher Copyright: © 2020 Commonwealth of Australia. © 2020 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)

PY - 2020/10/1

Y1 - 2020/10/1

N2 - Recent European and US studies reported increased risks of skin cancers associated with hydrochlorothiazide (HCTZ) treatment. Our study aimed to determine the risk of lip cancer and malignant melanoma among Australians prescribed HCTZ. We conducted a case-control study nested within a population of veterans residing in New South Wales in 2004-2015, using Australian Department of Veterans’ Affairs data linked with cancer registrations, hospitalisation and prescription dispensings. Among DVA healthcare card holders 65 years and older, we identified incident cases of squamous cell carcinoma of the lip and of cutaneous melanoma, each matched with up to 20 controls through risk-set sampling. We estimated odds ratios (ORs) associating HCTZ use with each cancer using conditional logistic regression, adjusting for predefined confounders. For lip cancer (45 cases), ever-use of HCTZ yielded an OR of 2.6 (95% CI: 1.4-5.0) and high HCTZ use (≥25 000 mg) an OR of 4.7 (95% CI: 1.6-13.7). For cutaneous melanoma (659 cases), ever-use of HCTZ resulted in an OR of 1.2 (95% CI 1.0-1.5) and high HCTZ use in an OR of 1.2 (95% CI: 0.8-1.8). Our findings align with risk estimates from previous studies and provide further evidence that HCTZ’s photosensitising properties may promote carcinogenesis in sun-exposed tissues.

AB - Recent European and US studies reported increased risks of skin cancers associated with hydrochlorothiazide (HCTZ) treatment. Our study aimed to determine the risk of lip cancer and malignant melanoma among Australians prescribed HCTZ. We conducted a case-control study nested within a population of veterans residing in New South Wales in 2004-2015, using Australian Department of Veterans’ Affairs data linked with cancer registrations, hospitalisation and prescription dispensings. Among DVA healthcare card holders 65 years and older, we identified incident cases of squamous cell carcinoma of the lip and of cutaneous melanoma, each matched with up to 20 controls through risk-set sampling. We estimated odds ratios (ORs) associating HCTZ use with each cancer using conditional logistic regression, adjusting for predefined confounders. For lip cancer (45 cases), ever-use of HCTZ yielded an OR of 2.6 (95% CI: 1.4-5.0) and high HCTZ use (≥25 000 mg) an OR of 4.7 (95% CI: 1.6-13.7). For cutaneous melanoma (659 cases), ever-use of HCTZ resulted in an OR of 1.2 (95% CI 1.0-1.5) and high HCTZ use in an OR of 1.2 (95% CI: 0.8-1.8). Our findings align with risk estimates from previous studies and provide further evidence that HCTZ’s photosensitising properties may promote carcinogenesis in sun-exposed tissues.

KW - Australia

KW - hydrochlorothiazide

KW - lip cancer

KW - malignant melanoma

KW - skin cancer

UR - http://www.scopus.com/inward/record.url?scp=85088816104&partnerID=8YFLogxK

U2 - 10.1111/bcpt.13463

DO - 10.1111/bcpt.13463

M3 - Article

C2 - 32608576

AN - SCOPUS:85088816104

SN - 1742-7835

VL - 127

SP - 320

EP - 328

JO - Basic and Clinical Pharmacology and Toxicology

JF - Basic and Clinical Pharmacology and Toxicology

IS - 4

ER -

Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide: A population-based case-control study

Abstract

Bibliographical note

Other keywords

Access to Document

Fingerprint

Cite this